News Search Results
Apr 08, 2026, 09:31 ET EVERGLADE WELCOMES DR. PATRICK SIMS, EXPANDING ITS TECHNICAL AND FEDERAL EXPERTISE
engagement."With the addition of Dr. Sims, EverGlade continues to expand its capabilities in supporting advanced R&D programs across biotechnology, national security, and life sciences.About EverGladeEverGlade connects breakthrough innovation with non-dilutive funding.
More news about: EverGlade Consulting
Apr 08, 2026, 09:15 ET ABK Biomedical and COR Development Partner to Establish Long-Term Commercial Manufacturing Facility in Ashland, Missouri
project is expected to bring new high-tech jobs to the Columbia area and strengthen Missouri's reputation as a premier hub for nuclear medicine and biotechnology.About ABK Biomedical, Inc.ABK Biomedical is a corporation focused on researching, developing and commercializing medical device
More news about: ABK Biomedical Inc.
Apr 08, 2026, 08:00 ET Stealth BioTherapeutics Appoints David A. Brown, Ph.D., as Chief Scientific Officer to Advance the Company's Pioneering Work in Mitochondrial Medicine
Mass., April 8, 2026 /PRNewswire/ -- Stealth BioTherapeutics (the "Company" or "Stealth"), a commercial-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today
More news about: Stealth BioTherapeutics Inc.
Apr 08, 2026, 08:00 ET Flow Sciences Appoints Michael Gesser as Chief Financial Officer
facilities, and a consultative design center, strengthening Flow Sciences' presence in a region with deep concentrations of pharmaceutical and biotechnology clients."Michael's appointment as CFO is a natural evolution of his already-significant contributions to Flow Sciences," said Jonathan Mann,
More news about: Flow Sciences Inc
Apr 08, 2026, 06:59 ET Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that
More news about: Q32 Bio
Apr 08, 2026, 04:00 ET Ribbon Bio Appoints Dr. Urs Spitz as Chair of the Board
nearly three decades of experience building and scaling life sciences businesses across precision instruments, fine chemicals, diagnostics, and biotechnology. As CEO and co-owner of Biosynth, he led the company's transformation from a small regional business into a global supplier of critical raw materials,
More news about: Ribbon Bio
Apr 07, 2026, 19:00 ET WesternU College of Graduate Nursing ranked among U.S. News & World Report's Best Nursing Schools
Calif. and Western University of Health SciencesLebanon, Ore., is an independent nonprofit health professions university, conferring degrees in biotechnology and pharmaceutical sciences, dental medicine, medical sciences, nursing, optometry, osteopathic medicine, pharmacy, physical therapy, physician
More news about: Western University of Health Sciences
Apr 07, 2026, 14:33 ET Lupin Announces the Approval of Dapagliflozin Tablets in the United States
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Pharmaceuticals, Inc.
Apr 07, 2026, 14:00 ET WesternU COMP and COMP-Northwest remain among top in nation for primary care training
www.westernu.edu), located in Pomona, Calif. and Lebanon, Ore., is an independent nonprofit health professions university, conferring degrees in biotechnology and pharmaceutical sciences, dental medicine, medical sciences, nursing, optometry, osteopathic medicine, pharmacy, physical therapy, physician
More news about: Western University of Health Sciences
Apr 07, 2026, 12:10 ET IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
[email protected] 844-916-0895ImmunityBio, Inc. (IBRX) Securities Class Action: ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system
More news about: Hagens Berman Sobol Shapiro LLP
Apr 07, 2026, 12:00 ET Perimeter Systems, Inc. Launches as Global, End-to-End Biosecurity Infrastructure Platform to Address Escalating Global Biodefense Needs
The biological risk landscape is expanding – driven by the convergence of AI and biotechnology, the proliferation of high-containment laboratories, intensifying geopolitical competition, and increasingly globalized and inter-connected populations.
More news about: Perimeter Systems, Inc.
Apr 07, 2026, 10:30 ET EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a private Germany-based, clinical-stage biotechnology companyEQT Life Sciences led the Series B2 financing of Tubulis in March 2024, and has since suppEQTorted the Company at board level in its growth
More news about: EQT
Apr 07, 2026, 10:27 ET EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a private Germany-based, clinical-stage biotechnology companyEQT Life Sciences led the Series B2 financing of Tubulis in March 2024, and has since suppEQTorted the Company at board level in its growth
More news about: EQT
Apr 07, 2026, 09:27 ET Live Cell Observation System Selected for NASA-Supported Project Heading to the International Space Station
diseases in living organisms. For this reason, it is attracting attention from global life science companies, including pharmaceutical companies and biotechnology firms aiming to develop pharmaceuticals, as cutting-edge research.Through this project, Nikon will leverage the technical advantages and
More news about: Nikon Instruments Inc.
Apr 07, 2026, 09:05 ET Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion
announced that its subsidiary, BioSymetrics, has entered into a revenue-generating, commercial defense-focused collaboration with a specialized biotechnology partner to support the development of an advanced AI-enabled platform for chemical threat assessment, with initial engagement underway and additional
More news about: Lunai Bioworks Inc.
Apr 07, 2026, 09:00 ET More Patients Open to Non-GLP-1 Obesity Treatments After Learning About Alternatives, Phenomix Survey Finds
Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today released new findings from its "2026 State of Obesity Treatment Report: Progress, Gaps, and the Path to Personalized Care" report.
More news about: Phenomix Sciences
Apr 07, 2026, 09:00 ET Kytopen Expands Commercialization Efforts and Board of Directors Following Series B Investment Led by Telegraph Hill Partners
across a range of cell types, payloads, and therapeutic applications. Kytopen has recently disclosed strategic partnerships with industry-leading biotechnology companies, contract development and manufacturing organizations (CDMOs), and cell therapy-focused medical centers. Kytopen continues to engage strategic
More news about: Kytopen
Apr 07, 2026, 09:00 ET New Study Shows Increasing Value of Real-World Data (RWD) in Clinical Trials
dedicated to revolutionizing patient care and clinical research through real-world data (RWD). Researchers interviewed leaders at 18 pharmaceutical, biotechnology, and contract research organizations (CRO) focused on oncology, ophthalmology, urology, neurology, and dermatology therapeutic areas.Participating
More news about: Verana Health
Apr 07, 2026, 08:55 ET Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Anixa's Chairman and CEO, will participate in the
More news about: Anixa Biosciences, Inc.
Apr 07, 2026, 08:53 ET C3 Davos of Healthcare™ to Convene Global Leaders in Silicon Valley with Keynote by Secretary Leon Panetta
April 7, 2026 /PRNewswire/ -- The C3 Davos of Healthcare™ Silicon Valley Summit will convene global leaders across healthcare, biotechnology, artificial intelligence, academia, and institutional capital for a high-level strategic dialogue on the intersection of medical innovation, economic
More news about: C3 International Davos of Healthcare™
Apr 07, 2026, 08:40 ET NeuroTherapia announces completion of its Phase 2a Trial of a novel treatment for Alzheimer's Disease
and deadly central nervous system (CNS) diseases patients and their families face today. NeuroTherapia, Inc. is a clinical-stage, privately held biotechnology company, spun out of the Cleveland Clinic, developing oral, small-molecule drugs to address neuroinflammatory conditions of the CNS, including Alzheimer's
More news about: NeuroTherapia, Inc.
Apr 07, 2026, 08:10 ET Paul Spreen Appointed Chief Commercial Officer of Premier Research
pathways to new opportunities and foster long-term value for Premier."Throughout his career, Spreen has held leadership positions across biotechnology, CROs, and pharma services. During his time with IQVIA (previously Quintiles) he held several global leadership roles, most recently EVP and Chief
More news about: Premier Research International LLC
Apr 07, 2026, 08:05 ET Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
over four years with 25% of the grant vesting each year.About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Apr 07, 2026, 08:03 ET Jones Appoints Boris Peaker, PhD, CFA as Managing Director, Biotechnology Analyst
Institutional Services LLC ("Jones") today announced the appointment of Boris Peaker, PhD, CFA, as Managing Director, Biotechnology Analyst. Dr. Peaker will be responsible for covering biotechnology companies within the Healthcare sector, with a focus on emerging technologies in oncology, immunology, and genetic
More news about: JonesTrading Institutional Services
Apr 07, 2026, 08:00 ET Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference
("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that in collaboration with its joint venture partner, Austrianova, a global biotechnology company, it will present the latest data
More news about: Avai Bio, Inc.